Uroprotective and Hepatoprotective Potential of Anagallis arvensis against the Experimental Animal Model

Table 4

Effect of A. arvensis on LFTs.

Groups	Bilirubin (mg/dl)	ALT (mg/dl)	AST (mg/dl)	ALP (mg/dl)
Control	0.46 ± 0.03	52.66 ± 0.31	105.00 ± 1.15	188.00 ± 4.61
Diseased control	0.80 ± 0.058	58.66 ± 0.66	147.66 ± 3.38	267.66 ± 4.97
Standard drug-treated	0.53 ± 0.033	53.33 ± 0.33	102.33 ± 0.88	121.66 ± 2.18
MEOAA (250 mg/kg)	0.43 ± 0.030	51.00 ± 0.55	107.00 ± 0.57	177.33 ± 7.42
MEOAA (500 mg/kg)	0.33 ± 0.032	52.00 ± 0.57	104.33 ± 1.85	103.66 ± 2.17

Data have been presented as mean ± SEM. Determination of the level of bilirubin, ALT, AST, and ALP in control, diseased control (paracetamol 250 mg/kg), standard drug (silymarin 50 mg/kg), and methanol extract of A. arvensis (MEOAA) (250 mg/kg and 500 mg/kg) treated groups of rats ( compared to the control group, compared to the diseased control group; n = 4).